Extraintestinal Manifestations of Inflammatory Bowel Disease
Year: 2008
Type: review
Abstract: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) have been reported to involve almost every organ system. This article focuses on the prevalence (where known) and clinical aspects of the more commonly described EIMs of Crohn disease (CD) and ulcerative colitis (UC). Because of limited data from pediatric populations, much of the information in this review is from adult reports. An important consideration is whether EIMs represent manifestations of the same pathogenetic mechanisms or distinctly different disease processes from the underlying IBD, possibly coincidental to the presence of IBD or as a consequence of the IBD or its treatment. EIMs may present before the onset of gastrointestinal symptoms, during the natural course of disease, and rarely may even follow colectomy in patients with UC. Tables 1 and 2 The prevalence of at least 1 EIM in recent population-based studies of patients with IBD ranges from 6% to 47% (1–4). Several reports from pediatric centers suggest a greater prevalence in younger patients. Grossman and DeBenedetti (5) reported that 68% of 41 children with IBD had EIMs, and a recent review of pediatric patients by Stawarski et al (6) reported that 50% with UC and 80% with CD had at least 1 EIM.TABLE 1: Extraintestinal manifestation of inflammatory bowel diseaseTABLE 2: Prevalence of extraintestinal manifestations of inflammatory bowel diseaseIn this review, we provide an overview of EIMs that have been reported to be associated with UC and CD, emphasizing the pediatric experience when such information is available. EIMs are subdivided into several categories: colitis related, specifically skin, eye, joint, and mouth, where the activity of the EIM parallels the activity of the underlying intestinal disease; hepatobiliary; impaired growth; EIMs secondary to complications of or as direct extensions of bowel disease, more frequently noted in patients with CD than with UC and including nephrolithiasis, obstructive uropathy, cholelithiasis, and pancreatitis; and EIMs that cannot be categorized clearly in one of the other groups, such as amyloidosis and cancer (7). EIMs involving vascular, hematological, pulmonary, cardiac, and neurological systems probably belong to this last group. Impaired growth, unique to the pediatric age group, may be an EIM potentially related to all of these categories. Iatrogenic EIMs, such as drug-induced bone marrow suppression and corticosteroid-associated myopathy, are not discussed (Table 1). PATHOGENESIS The pathogenesis of EIMs associated with IBD is poorly understood. Many EIMs are hypothesized to be due to immune reactions, supported by the observations that primarily immunological derangements progress to the development of IBD and that patients with IBD have an increased risk of autoimmune diseases (8). Malabsorption, protein-losing enteropathy, fistulas, and intestinal resection each can result in deficiencies of nutrients, proteins, bile salts, vitamins, and minerals with corresponding clinical consequences. Medications used in the treatment of IBD may be associated with many nonintestinal as well as intestinal side effects. Animal studies support the theory that intestinal bacteria also play a pathological role in the development of EIMs. In HLA-B27 transgenic and T cell receptor-α mutant colitis mouse models, the expression of extraintestinal (and intestinal) disease requires the presence of commensal bacteria; these mouse models do not manifest intrinsic intestinal or extraintestinal pathologies in germ-free environments (9). Genetic factors also have been implicated in the pathogenesis of EIMs in IBD. Ethnic and racial differences in IBD phenotype have potential implications for diagnosis and management of IBD and its complications (10). Studies reveal associations of EIMs in IBD with major histocompatibility complex loci. For examples, patients with CD who have EIMs are more likely to have HLA-A2, HLA-DR1, and HLA-DQw5, whereas patients with UC and EIMs are more likely to have HLA-DR103, B27, and B58 phenotypes (11,12). COLITIS-RELATED EXTRAINTESTINAL MANIFESTATIONS Dermatological Manifestations Skin involvement has been described in 10% to 15% of patients with IBD (7). The 2 most commonly encountered cutaneous manifestations of IBD are erythema nodosum and pyoderma gangrenosum. Erythema nodosum presents as a single or multiple tender red nodules typically on the extensor surface of the lower extremities. Reported to be more common in CD than UC, erythema nodosum correlates well with and usually reflects increasing bowel activity (1,5,7). Bernstein et al (1) reviewed EIMs in 4445 adult patients with IBD and found prevalence rates of erythema nodosum of 1.9% in patients with CD and UC. A report based on 41 children with IBD found 4 of 32 (12.5%) children with UC and 5 of 9 (56%) with CD had erythema nodosum (5). Several other reports, again, all in adults, report prevalence rates of 2% to 7.5% in CD and 0.9% to 4% for UC (2,7,13–15). The etiology of erythema nodosum is unknown, although a distinct HLA region on chromosome 6 (HLA-B15) is weakly associated with its development, supporting some genetic influence (12). These lesions usually respond to treatment of the underlying IBD. Although some success has been reported with oral potassium iodide, severe or refractory cases may require systemic corticosteroids or immunosuppressive therapy. Pyoderma gangrenosum usually begins as an erythematous pustule or nodule that spreads rapidly to adjacent skin and develops into a burrowing ulcer with irregular violaceous edges. Although the appearance can be dramatic, the ulcers are sterile. Lesions are found typically on the extensor surfaces of the extremities, but may appear in other portions of the body, especially sites of trauma. Pyoderma gangrenosum has been reported to evolve from preceding erythema nodosum (16). Pyoderma gangrenosum is reported in 0.5% to 5% of patients with IBD (2,7,15). Most reports suggest that it is more common in patients with UC than those with CD, however, in the study by Bernstein et al (1) of 4445 patients a higher prevalence was found among patients with CD. Specific prevalence data in children are lacking. Four distinctive variants of pyoderma gangrenosum are recognized: bullous, familial, malignant, and superficial granulomatous pyoderma. Pyoderma gangrenosum may develop before bowel symptoms, during quiescent disease, or even following colectomy. About 40% of IBD patients with pyoderma gangrenosum develop arthritis (14). Lesions are multiple in the majority of patients, and most appear below the knee. Histological characteristics include lymphocytic vasculitis peripherally in the erythematous zone, neutrophilic infiltration, and a central abscess. Direct immunofluorescence may show immunoglobulin and complement deposits involving superficial and deeper dermal vessels. Pyoderma gangrenosum often resolves with treatment of the underlying IBD. Mild cases usually respond to local and topical therapy, including intralesional corticosteroid, topical cromolyn sodium, and topical 5-aminosalicylic acid. Effective systemic agents include oral sulfasalazine, dapsone, corticosteroid, and immunomodulators such as azathioprine, cyclophosphamide, cyclosporine, methotrexate, tacrolimus, and mycophenolate mofetil (17). Successful treatment with infliximab in both children and adults has been documented (18,19). Metastatic CD is a granulomatous dermatitis seen in adults, although isolated cases have been described in children (20). Acute febrile neutrophilic dermatosis (Sweet syndrome) is a rare EIM of IBD and presents as tender, erythematous plaques or nodules involving the arms, legs, trunk, hands, or face (21). It may parallel the intestinal disease or may precede the diagnosis of IBD. Skin biopsies reveal neutrophilic infiltrate with leukocytosis. Azathioprine has been implicated as a possible cause of Sweet syndrome in a patient with CD. Most cases respond to systemic corticosteroids, and metronidazole is reported to be effective in 1 case (22–24). Other cutaneous manifestations associated with IBD include psoriasis, epidermolysis bullosa, polyarteritis nodosa, alopecia, and erythema elevatum diutinum (25,26). Ophthalmological Manifestations Ophthalmologic involvement related to IBD is reported in 1.6% to 4.6 % of patients with UC and 3% to 6.3% of patients with CD (2,4,15,27,28). Patients with CD with colonic involvement are more likely to develop ocular problems than those with small bowel disease alone. Data suggest that asymptomatic transient uveitis is common in children with granulomatous bowel disease, but progression to severe adult uveal disease is poorly documented. Ophthalmological changes also may result from treatment rather than directly from the underlying IBD. Involvement of the vascular coats of the eye in IBD may be from bacteria or genetic and immunological factors in the manifestation of extraintestinal symptoms of IBD (29,30). The most common ocular lesions associated with IBD are episcleritis and uveitis. Episcleritis is characterized by painless hyperemia of the sclera and conjunctiva without loss of vision. Uveitis manifests as an acute or subacute painful eye with visual blurring, photophobia, headache, and iridospasm. Visual acuity is not affected unless the retina or the posterior uveal structures are involved. Diagnosis is made on slit lamp examination, showing flare and cells in the anterior chamber. Acute anterior uveitis is an ophthalmological emergency requiring prompt intervention. Prompt treatment of uveitis with systemic or topical steroids is essential to prevent progression to blindness. Episcleritis rarely progress to blindness if untreated. Ocular complications also may develop in patients with IBD due to chronic corticosteroid usage. Increased intraocular pressures are reported in 22% of pediatric patients exposed to varying doses of corticosteroids (31). The risk of corticosteroid-induced glaucoma leading to irreversible visual loss and corticosteroid-associated cataract should prompt careful ophthalmological evaluation at regular intervals in patients with chronic corticosteroid use. Recent reports of glaucoma also have been noted among children not exposed to corticosteroids, again suggesting an immunological mechanism for its development. Musculoskeletal Manifestations The most common EIMs in IBD are musculoskeletal disorders. Spondyloarthropathy is reported in 5% to 20% of patients with IBD (7,15,27,28,32). The 2 patterns described in both children and adults are a peripheral arthritis, sometimes referred to as “colitis arthritis,” and the axial form, “ankylosing spondylitis” or “sacroiliitis” (33). The peripheral arthropathy associated with IBD has been subclassified into 2 distinct types. Type 1 is pauciarticular arthritis. It affects fewer than 5 joints, is asymmetrical, and typically affects large joints (knee, elbow, and ankles). It usually manifests with acute self-limiting episodes lasting a median of 5 weeks. Approximately 20% to 40% of all patients have more than 1 episode of arthritis. In one of the few early reports in children (n = 41), 5 of 32 (16%) with UC and 2 of 9 (22%) with CD had arthritis (5). The risk of developing peripheral arthropathy appears to increase with the extent of colonic disease. It also is increased in association with disease complications or other EIMs including abscesses, perianal disease, erythema nodosum, stomatitis, uveitis, and pyoderma gangrenosum. In contrast, type 2 peripheral arthropathy is polyarticular, involving 5 or more joints, more typically the small joints. Polyarticular arthritis with IBD is independent of intestinal disease activity but has been associated with uveitis (12). Symptoms of polyarticular arthritis are reported to persist for a median of 3 years. The development of articular manifestations in patients with UC appears to be influenced by genetic factors present in some major histocompatibility complex haplotypes (34). Type 1 peripheral arthritis is associated with HLA-B27, HLA-B35, and HLA-DR, whereas type 2 is associated with HLA-B44. Axial arthropathy, both spondylitis and isolated sacroiliitis, is less frequent than peripheral arthropathy and is reported in 3% to 25% of patients (7,15,27,28). with polyarticular disease, axial arthropathy not parallel IBD disease spondylitis is reported in 5% to 10% of patients with most are and and most are HLA-B27 spondylitis in the patients has a disease course that is to spondylitis seen in the Patients with spondylitis often experience severe onset of associated with or by of Symptoms usually are to the underlying IBD disease in early may be or show arthropathy usually to and treatment of the underlying Other treatment include therapy, and used in the management of peripheral arthropathy require of the reported association of of IBD and although studies provide information this In to peripheral arthropathy, usually to treatment of or of the underlying IBD not the of the axial Other have sulfasalazine, methotrexate, azathioprine, and with infliximab or and have been reported in to of adult patients with IBD was in of children with CD and in 25% with UC In a study of found in of with of among patients with UC and among those with CD In study of children with IBD of with and 3 with and the of was in and 20% in to adult reports. A of is reported in and patients is a systemic disease characterized by bone and leading to increased bone and to can be bone The for bone loss are based on and are in to in or and is as a of to and is a lower than The pathogenesis of or in IBD is not well understood. Several factors may with bone and bone in patients with IBD. potential pathogenetic factors in IBD include by IBD, manifestation with of in of corticosteroid and disease activity and related of inflammatory Patients with CD may develop or even without treatment with Patients with CD should bone with studies 1 to several a of bone should be and more has been at to intervals for pediatric patients with to corticosteroids, although even adult patients with corticosteroid treatment to a of of for 6 also may develop bone loss and should be should be to that patients corticosteroids have and of bone loss should with an to corticosteroid-induced bone loss by the corticosteroid with immunomodulators or an to and have been in patients with IBD for the treatment of although in pediatric patients to be referred to as or is characterized by of and cells in the bone and bone It has been described in both children and adults with IBD, with a reported prevalence in 1 of of all patients and to 4% of patients corticosteroids of this potentially EIM is important for Diagnosis is made by bone and may include management such as and also have been Manifestations is seen in at least 5% to 10% of patients with UC and 20% to with CD. lesions may before the onset of intestinal symptoms of IBD or may parallel intestinal disease Symptoms include to severe of these lesions often reveal in patients with CD, with systemic or local corticosteroids or other immunosuppressive has been is a chronic disease characterized by and dermatosis of the skin and oral lesions are distinct and appear as multiple with an erythematous that and to a has a association with gastrointestinal disease and is a for underlying most reported cases have been associated with UC. also has been associated with in a patient with underlying oral CD is based on the underlying gastrointestinal disease and systemic agents such as sulfasalazine, corticosteroids, azathioprine, and treatment in severe cases of UC colectomy and has in of the MANIFESTATIONS complications are among the more EIMs in patients with UC or CD, and include small and large and The most common among pediatric patients is a of both and bile of in children has that much of was as on Data from centers the most affected patients suggest a of in 1.6% to of patients with UC et al in a study of patients of age and reported that the prevalence of the disease was in patients with colitis and 0.5% in patients with A is in patients with colitis and with those who have colitis without The etiology of is The may be by an of the by transient or the of in with colonic disease. are in many patients with and UC are more frequent in patients with than in patients with IBD without disease; 25% of patients with have at least 1 autoimmune the and The diagnosis of should be in patients with specifically the or In the and are is and are and the HLA is found in of patients with biopsies reveal and peripheral inflammatory and varying of that have been in adult patients with include azathioprine, methotrexate, cyclosporine, tacrolimus, and of these has been to the course of disease, including patient and with experience in when with but disease course or and of have clinical of of by or for has et al reported a experience with treatment for in 32 adult patients with for a of in of patients at 2 80% of for 1 and for 3 years. are are associated with an increased risk of and may more can children with with patient and oral in children with has some in disease and are common and can progress to disease. the to and the risk for developing acute or chronic following CD is a risk for developing can evolve into In a study of adult patients with IBD, et al found in of UC and of patients with CD. reported in of CD and of patients with UC. The of was not related to the and activity of the disease or the type of used et al a association in both disease and and treatment in UC patients. of is important in IBD, even in the of is more likely a of the in small intestinal disease and is reported in of adults with CD A recent study in adults that patients with CD are at higher risk for with UC or In a study of patients with IBD, et al found that had of 41 had CD and had UC. The mechanism of in CD may be related to an bile resection or disease, and is likely a result of Impaired growth, although also in UC, is more common in CD of are found in poorly children with CD and with In children with IBD with EIMs, Stawarski et al (6) reported in with UC and 80% with CD. are reported to be in impaired and children with CD. is the in oral due to of of gastrointestinal or a protein-losing can to may to of corticosteroids for as as to is associated with type 1 a for corticosteroid appear to have less on is not in disease activity to and development. Recent for children with CD show some of this treatment treatment may be and may children on corticosteroids with is in UC, of in this of patients. in CD, if the disease is limited to a and of the has been to and in or children EXTRAINTESTINAL MANIFESTATIONS and Manifestations obstructive uropathy, and of the directly result from the underlying disease Reported from 4% to in adult patients but in to 2% of children with IBD is due to or is due to typically associated with CD or in the presence of in the The with to the can be as and into the Because is in the in patients with an Patients with an are to of of frequent The onset of severe or in patients with IBD, if different from the should to of a in the The management of in patients with IBD is different from that in the and of of for and Patients with an should be to of manifestations in patients with IBD may include and obstructive with is associated with of the inflammatory involving the and and may result in severe to cause usually is for obstructive in patients with IBD. disease the in patients with CD may present with or may be if not the or such as infliximab or complex with and has been described in children and adults with CD or UC Diagnosis is by and treatment parallels the underlying IBD. systemic amyloidosis is a rare but that has been reported in 0.9% and of patients with CD and UC in patients with IBD often affects the and presents with by syndrome and or Diagnosis is made with or although a is the most and may be associated with both UC and CD. The most common cause is and to used to IBD of including sulfasalazine, and may present as or more commonly asymptomatic disease in adults with IBD. et al reported in of pediatric patients with IBD. In a study of Stawarski et al reported acute in with CD and with UC. have been found in to 40% of patients with CD studies are to whether from for IBD, have a role in its pathogenesis and potentially patients at Diagnosis is by with contrast, or Manifestations Although involving all cell may be is the most common manifestation of IBD. Stawarski et al (6) reported secondary in 5% of patients with UC and with CD. to the development of the of include chronic gastrointestinal or secondary to disease or due to disease or therapy, or autoimmune and are usually due to or often are lower in patients with IBD than in with severe of on the underlying requires whereas of may be in other types. has been used in some patients with IBD and refractory and from a in patients with IBD can to or in the has been reported in of patients with UC and of patients with CD. and are less frequently reported among pediatric patients, with 3 patients with UC and 1 with CD described in case reports such as therapy, and of central are risk factors in patients with IBD. The development of may be related to and an increase in during and are in the pathogenesis of IBD, and some such as are A population-based study in adults that IBD patients have greater risk with without IBD for developing and is the most frequent cause of but studies have in the prevalence of patients with IBD and of disease activity and Medications that factors such as and have been used in The risk of intestinal should be with the of these Manifestations and adults with IBD have been rarely reported to develop at or during or quiescent disease The pathogenesis of is unknown, although and have been implicated in some cases The clinical may include or in severe cases requiring have been used as therapy, although this should be the risk of the underlying IBD. Manifestations of appears to parallel underlying disease activity in patients with IBD. disease, although is at least 2 of and and Other that have been associated with IBD include and granulomatous disease. These pathological processes do not typically to the or activity of the underlying IBD. and other should be in patients immunosuppressive Manifestations and peripheral neurological are described in patients with IBD and include peripheral central and loss mechanisms are for involvement with IBD. deficiencies associated with neurological such as should be has been reported in both a and an adult with of severe due to of a from the to the neurological is important in patients developing secondary to CD. Medications for treatment of IBD also are associated with neurological A greater risk for development of a peripheral is with chronic and higher metronidazole Although 50% of patients with metronidazole for develop have a peripheral on Symptoms may persist even of the UC and CD commonly manifest and symptoms of extraintestinal disease. Patients with of disease to the gastrointestinal should be to have an associated of underlying IBD. Patients with or symptoms of EIMs should be for IBD if not Data on EIMs of IBD in children are with those in adults (Table and may be in of recent studies suggesting unique aspects of IBD with patients to the and prevalence of EIMs of IBD in children is essential to of the natural and associated EIMs in children with IBD.
Authors: Folashade A Jose, Melvin B Heyman
Institution: University of California, San Francisco
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: extraintestinal manifestations, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pediatric inflammatory bowel disease, prevalence, cutaneous manifestations, ocular manifestations, joint manifestations, hepatobiliary manifestations, kidney stones, urinary tract obstruction, gallstones, pancreatitis, amyloidosis, cancer risk, iatrogenic complications
Open Access status: green
OpenAlex ID: W2016704345
